irinotecan liposome + fruquintinib

This combination therapy pairs irinotecan liposome (Onivyde), a topoisomerase I inhibitor encapsulated in a long-circulating liposomal formulation, with fruquintinib, a highly selective small-molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. Irinotecan liposome provides sustained exposure to the active metabolite SN-38 within the tumor microenvironment, where it interferes with DNA replication and induces cell death. Fruquintinib complements this by inhibiting tumor angiogenesis, thereby restricting the blood supply necessary for tumor growth and metastasis. The combination is primarily being investigated for the treatment of metastatic colorectal cancer (mCRC) and colorectal adenocarcinoma, particularly in patients who have progressed on prior standard therapies. Clinical research, including Phase 2 trials, is being conducted by institutions such as Guangxi Medical University Cancer Hospital to evaluate the efficacy and safety of this regimen.

Brand names

ElunateFruzaqla

Other names

Onivyde + furoquininibirinotecan liposome + fruquintinibMM-398 + HMPL-013